Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Xvivo Perfusion stock

XVIVO.ST
SE0004840718
A1J5GZ

Price

0
Today +/-
-0
Today %
-0 %

Xvivo Perfusion stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Xvivo Perfusion stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Xvivo Perfusion stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Xvivo Perfusion stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Xvivo Perfusion's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Xvivo Perfusion Stock Price History

DateXvivo Perfusion Price
12/10/20240 undefined
12/9/20240 undefined
12/6/20240 undefined
12/5/20240 undefined
12/4/20240 undefined
12/3/20240 undefined
12/2/20240 undefined
11/29/20240 undefined
11/28/20240 undefined
11/27/20240 undefined
11/26/20240 undefined
11/25/20240 undefined
11/22/20240 undefined
11/21/20240 undefined
11/20/20240 undefined
11/19/20240 undefined
11/18/20240 undefined
11/15/20240 undefined
11/14/20240 undefined
11/13/20240 undefined
11/12/20240 undefined

Xvivo Perfusion Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Xvivo Perfusion, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Xvivo Perfusion from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Xvivo Perfusion’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Xvivo Perfusion. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Xvivo Perfusion’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Xvivo Perfusion’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Xvivo Perfusion’s growth potential.

Xvivo Perfusion Revenue, EBIT and net profit per share

DateXvivo Perfusion RevenueXvivo Perfusion EBITXvivo Perfusion Net Income
2027e0 undefined0 undefined0 undefined
2026e0 undefined0 undefined0 undefined
2025e0 undefined0 undefined0 undefined
2024e0 undefined0 undefined0 undefined
20230 undefined0 undefined0 undefined
20220 undefined0 undefined0 undefined
20210 undefined0 undefined0 undefined
20200 undefined0 undefined0 undefined
20190 undefined0 undefined0 undefined
20180 undefined0 undefined0 undefined
20170 undefined0 undefined0 undefined
20160 undefined0 undefined0 undefined
20150 undefined0 undefined0 undefined
20140 undefined0 undefined0 undefined
20130 undefined0 undefined0 undefined
20120 undefined0 undefined0 undefined

Xvivo Perfusion Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2012201320142015201620172018201920202021202220232024e2025e2026e2027e
0000000000000000
----------------
----------------
0000000000000000
0000000000000000
----------------
0000000000000000
----------------
Details

Keystats

ⓘ

Revenue and Growth

The Xvivo Perfusion Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Xvivo Perfusion is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
201220132014201520162017201820192020202120222023
                       
000000000000
000000000000
000000000000
000000000000
000000000000
000000000000
000000000000
000000000000
000000000000
000000000000
000000000000
000000000000
000000000000
000000000000
                       
000000000000
000000000000
000000000000
000000000000
000000000000
000000000000
000000000000
000000000000
000000000000
000000000000
000000000000
000000000000
000000000000
000000000000
000000000000
000000000000
000000000000
000000000000
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Xvivo Perfusion provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Xvivo Perfusion's financial health and stability.

Assets

Xvivo Perfusion's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Xvivo Perfusion must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Xvivo Perfusion after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Xvivo Perfusion's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
201220132014201520162017201820192020202120222023
000000000000
000000000000
000000000000
000000000000
000000000000
000000000000
000000000000
000000000000
000000000000
000000000000
000000000000
000000000000
000000000000
000000000000
000000000000
------------
000000000000
000000000000
000000000000
000000000000

Xvivo Perfusion stock margins

The Xvivo Perfusion margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Xvivo Perfusion. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Xvivo Perfusion.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Xvivo Perfusion's sales revenue. A higher gross margin percentage indicates that the Xvivo Perfusion retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Xvivo Perfusion's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Xvivo Perfusion's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Xvivo Perfusion's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Xvivo Perfusion. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Xvivo Perfusion's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Xvivo Perfusion Margin History

Xvivo Perfusion Gross marginXvivo Perfusion Profit marginXvivo Perfusion EBIT marginXvivo Perfusion Profit margin
2027e0 %0 %0 %
2026e0 %0 %0 %
2025e0 %0 %0 %
2024e0 %0 %0 %
20230 %0 %0 %
20220 %0 %0 %
20210 %0 %0 %
20200 %0 %0 %
20190 %0 %0 %
20180 %0 %0 %
20170 %0 %0 %
20160 %0 %0 %
20150 %0 %0 %
20140 %0 %0 %
20130 %0 %0 %
20120 %0 %0 %

Xvivo Perfusion Stock Sales Revenue, EBIT, Earnings per Share

The Xvivo Perfusion earnings per share therefore indicates how much revenue Xvivo Perfusion has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Xvivo Perfusion earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Xvivo Perfusion's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Xvivo Perfusion’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Xvivo Perfusion's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Xvivo Perfusion Revenue, EBIT and net profit per share

DateXvivo Perfusion Sales per ShareXvivo Perfusion EBIT per shareXvivo Perfusion Earnings per Share
2027e0 undefined0 undefined0 undefined
2026e0 undefined0 undefined0 undefined
2025e0 undefined0 undefined0 undefined
2024e0 undefined0 undefined0 undefined
20230 undefined0 undefined0 undefined
20220 undefined0 undefined0 undefined
20210 undefined0 undefined0 undefined
20200 undefined0 undefined0 undefined
20190 undefined0 undefined0 undefined
20180 undefined0 undefined0 undefined
20170 undefined0 undefined0 undefined
20160 undefined0 undefined0 undefined
20150 undefined0 undefined0 undefined
20140 undefined0 undefined0 undefined
20130 undefined0 undefined0 undefined
20120 undefined0 undefined0 undefined

Xvivo Perfusion business model

Xvivo Perfusion AB is a Swedish medical technology company that specializes in the development of solutions aimed at improving the transplantation of human organs. The company was founded in 1998 by Tetsuzo Akutsu, a renowned Japanese heart surgeon specializing in the treatment of cardiovascular diseases. Xvivo Perfusion is one of the most popular companies on Eulerpool.com.

Xvivo Perfusion SWOT Analysis

Strengths

Xvivo Perfusion AB has several strengths that contribute to its success and competitive advantage. Firstly, the company possesses advanced technologies and expertise in organ and lung perfusion systems, allowing them to effectively address the growing demand for organ transplantation. Secondly, Xvivo Perfusion AB has a strong global presence and a well-established network of distribution channels, enabling them to reach international markets efficiently. Lastly, the company has a talented and dedicated workforce, which plays a crucial role in driving innovation and maintaining superior product quality.

Weaknesses

Despite its strengths, Xvivo Perfusion AB also faces certain weaknesses that need to be addressed. One notable weakness is the company's reliance on a limited number of key customers, potentially exposing them to financial risks if these customers choose to seek alternative suppliers. Additionally, Xvivo Perfusion AB may face challenges in securing regulatory approvals for their products in certain markets, which can hinder their ability to expand globally. Lastly, the company could benefit from enhancing their marketing efforts to further increase brand awareness and capture larger market share.

Opportunities

There are several opportunities available for Xvivo Perfusion AB to capitalize on. Firstly, the growing demand for organ transplantation presents a significant market opportunity for the company to expand its customer base and increase sales. Secondly, advancements in medical research and technology provide an opportunity for Xvivo Perfusion AB to develop and introduce innovative perfusion systems with improved functionalities, setting them apart from competitors. Lastly, strategic partnerships and collaborations with hospitals, research institutions, and pharmaceutical companies can provide access to complementary expertise and resources, fostering innovation and driving market growth.

Threats

Xvivo Perfusion AB faces several threats that could impact its business. Firstly, intense competition within the medical technology industry poses a threat, as other companies with similar perfusion solutions may attempt to gain market share. Additionally, regulatory changes and stringent approval processes in certain countries can hinder Xvivo Perfusion AB's ability to enter new markets or cause delays in product launches. Furthermore, economic downturns or financial instability in key markets can impact customer demand for organ and lung perfusion systems. Lastly, disruptive technologies or breakthroughs in alternative transplantation methods could pose a long-term threat if Xvivo Perfusion AB fails to adapt and evolve its offerings accordingly.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Xvivo Perfusion Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Xvivo Perfusion historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Xvivo Perfusion shares outstanding

The number of shares was Xvivo Perfusion in 2023 — This indicates how many shares 29.935 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Xvivo Perfusion earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Xvivo Perfusion's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Xvivo Perfusion’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Xvivo Perfusion's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Xvivo Perfusion.

Xvivo Perfusion latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/20240 0  (288.36 %)2024 Q3
6/30/20240 0  (30.98 %)2024 Q2
3/31/20240 0  (132.41 %)2024 Q1
12/31/20230 0  (473.32 %)2023 Q4
9/30/20230 0  (-82.07 %)2023 Q3
6/30/20230 0  (-36.8 %)2023 Q2
3/31/20230 0  (-16.34 %)2023 Q1
12/31/20220 0  (-45.39 %)2022 Q4
9/30/20220 0  (55.34 %)2022 Q3
6/30/20220 0  (-27.18 %)2022 Q2
1
2
3
4
...
5

Eulerpool ESG Scorecard© for the Xvivo Perfusion stock

Eulerpool World ESG Rating (EESG©)

69/ 100

🌱 Environment

57

👫 Social

99

🏛️ Governance

50

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees49
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Xvivo Perfusion shareholders

%
Name
Stocks
Change
Date
14.26509 % Bure Equity AB4,493,50404/30/2024
9.04184 % Fj¿rde AP-Fonden2,848,1805,6274/30/2024
5.94300 % Eccenovo AB1,872,045-2,9554/30/2024
4.96884 % Swedbank Robur Fonder AB1,565,186-64,8188/16/2024
4.58457 % Handelsbanken Kapitalf¿rvaltning AB1,444,139254,8934/30/2024
2.77979 % Capital Research Global Investors875,634-385,3664/30/2024
2.28536 % Premier Asset Management Ltd719,889-4,8366/30/2024
1.84979 % Andra AP-Fonden582,684116,4274/30/2024
1.60317 % F¿rsta AP-Fonden505,000405,0004/30/2024
1.31810 % Nordnet Pensionsforsakring AB415,201-77,5764/30/2024
1
2
3
4
5
...
10

Xvivo Perfusion Executives and Management Board

Mr. Christoffer Rosenblad

(48)
Xvivo Perfusion Chief Executive Officer
Compensation 782,000

Mr. Goesta Johannesson

(64)
Xvivo Perfusion Chairman of the Board
Compensation 515,000

Ms. Camilla Oberg

(59)
Xvivo Perfusion Independent Director
Compensation 295,000

Mr. Goeran Dellgren

(62)
Xvivo Perfusion Independent Director
Compensation 260,000

Mr. Lars Henriksson

(68)
Xvivo Perfusion Independent Director
Compensation 260,000
1
2
3

Xvivo Perfusion Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Bure Equity Stock
Bure Equity
SupplierCustomer0,310,380,770,600,700,75
Swedbank A Stock
Swedbank A
SupplierCustomer-0,05-0,30-0,010,320,200,43
1

Most common questions regarding Xvivo Perfusion

What values and corporate philosophy does Xvivo Perfusion represent?

Xvivo Perfusion AB is a medical technology company that specializes in providing solutions for organ transplantation and preservation. The company's values revolve around innovation, patient focus, and quality. Xvivo Perfusion AB's corporate philosophy is centered on improving patient outcomes by developing and commercializing advanced products and services that ensure the safe and effective transport and preservation of organs. With a strong commitment to excellence and continuous improvement, Xvivo Perfusion AB strives to be a leader in the field of organ transplantation, contributing to the advancement of medical science and ultimately saving lives.

In which countries and regions is Xvivo Perfusion primarily present?

Xvivo Perfusion AB is primarily present in several countries and regions around the world. With a global presence, the company operates in Europe, North America, Latin America, and Asia-Pacific. Its reach extends to countries such as Sweden, the United States, Germany, France, the United Kingdom, Canada, Brazil, Australia, and many more. Xvivo Perfusion AB has established a strong international footprint, allowing it to cater to a diverse range of markets and provide its innovative perfusion solutions to healthcare professionals worldwide.

What significant milestones has the company Xvivo Perfusion achieved?

Some significant milestones achieved by Xvivo Perfusion AB include the development and commercialization of the XPS system, a medical device used for ex-vivo perfusion of organs. The company successfully received clearance from the FDA in 2014 to market the XPS system in the United States, significantly expanding its reach. In 2016, Xvivo Perfusion achieved another milestone by conducting the first-ever transplantation of human lungs, which were perfused and evaluated using their XPS system. These achievements demonstrate the company's expertise in the field of organ preservation and transplantation, positioning Xvivo Perfusion AB as a key player in advancing medical technologies for organ transplant procedures.

What is the history and background of the company Xvivo Perfusion?

Xvivo Perfusion AB is a renowned medical technology company specializing in solutions for organ transplantation. Established in 1998, Xvivo Perfusion has been a trusted name in the industry. The company focuses on developing advanced systems and solutions for organ preservation and evaluation prior to transplantation, ensuring optimal outcomes for patients and healthcare professionals alike. With its innovative technology and dedication to improving transplantation processes, Xvivo Perfusion has gained significant recognition globally. This Swedish-based company continues to play a vital role in advancing organ transplantation practices and contributing to enhanced patient care worldwide.

Who are the main competitors of Xvivo Perfusion in the market?

The main competitors of Xvivo Perfusion AB in the market include Organ Recovery Systems, XVIVO Surgical AB, TransMedics Group Inc., and OrganOx Limited.

In which industries is Xvivo Perfusion primarily active?

Xvivo Perfusion AB is primarily active in the healthcare and medical device industries.

What is the business model of Xvivo Perfusion?

Xvivo Perfusion AB specializes in providing innovative solutions for organ transplantation and advanced organ preservation. Their business model revolves around developing and commercializing state-of-the-art medical technology and systems that enable better organ transportation and preservation. Xvivo Perfusion AB offers products like the XPS™ (Xvivo Perfusion System), which enables safe evaluation and preservation of donor organs, and STEEN Solution™, a cold perfusion system used for lung preservation. By focusing on improving transplantation outcomes and extending organ viability, Xvivo Perfusion AB plays a crucial role in the organ transplantation field.

What is the P/E ratio of Xvivo Perfusion 2024?

The P/E ratio cannot be calculated for Xvivo Perfusion at the moment.

What is the P/S ratio of Xvivo Perfusion 2024?

The P/S cannot be calculated for Xvivo Perfusion currently.

What is the Quality Investing of Xvivo Perfusion?

The Quality Investing for Xvivo Perfusion is 4/10.

What is the revenue of Xvivo Perfusion 2024?

The revenue cannot currently be calculated for Xvivo Perfusion.

How high is the profit of Xvivo Perfusion 2024?

The profit cannot currently be calculated for Xvivo Perfusion.

What is the business model of Xvivo Perfusion

Xvivo Perfusion AB is a leading company in the development and manufacturing of products for organ perfusion that save lives. The company was founded in 1998 in Gothenburg, Sweden and employs over 230 employees worldwide. The company's business model is based on the production and marketing of clinical perfusion products for transplantation. The product range includes, among others, the XPS (Xvivo Perfusion System), a system for machine perfusion preparation and support of organs before transplantation. The company is particularly strong in the field of lung and liver perfusion and has brought several successful products to the market in this area. One of the new products is the Perfusix, a machine for the preparation of lungs that allows the use of organs from different sources and their evaluation before transplantation. The company is highly respected by customers due to its excellent performance and high product quality. Xvivo Perfusion AB follows a vertical business approach, fulfilling the needs of its customers through the development and production of clinical products for organ preparation. The customers are mainly transplant clinics that use the XPS to improve organ quality and increase patient survival rates. In addition, Xvivo Perfusion AB offers excellent training and consulting services to help customers maximize the full potential of their products. This extends the lifespan of the products and enables the market entry of new products. The company also has a strong commitment to research and development. They have partnerships with leading research institutes around the world to further enhance the performance of their products. This collaboration also provides an opportunity to develop new products and expand into other application areas. Overall, the business model of Xvivo Perfusion AB is very solid and tailored to the needs of customers. Through the development of new products and collaboration with research and development partners, the company is well positioned to expand its performance offering and meet the needs of customers.

What is the Xvivo Perfusion dividend?

Xvivo Perfusion pays a dividend of 0 SEK distributed over payouts per year.

How often does Xvivo Perfusion pay dividends?

The dividend cannot currently be calculated for Xvivo Perfusion or the company does not pay out a dividend.

What is the Xvivo Perfusion ISIN?

The ISIN of Xvivo Perfusion is SE0004840718.

What is the Xvivo Perfusion WKN?

The WKN of Xvivo Perfusion is A1J5GZ.

What is the Xvivo Perfusion ticker?

The ticker of Xvivo Perfusion is XVIVO.ST.

How much dividend does Xvivo Perfusion pay?

Over the past 12 months, Xvivo Perfusion paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Xvivo Perfusion is expected to pay a dividend of 0 SEK.

What is the dividend yield of Xvivo Perfusion?

The current dividend yield of Xvivo Perfusion is .

When does Xvivo Perfusion pay dividends?

Xvivo Perfusion pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Xvivo Perfusion?

Xvivo Perfusion paid dividends every year for the past 0 years.

What is the dividend of Xvivo Perfusion?

For the upcoming 12 months, dividends amounting to 0 SEK are expected. This corresponds to a dividend yield of 0 %.

In which sector is Xvivo Perfusion located?

Xvivo Perfusion is assigned to the 'Health' sector.

Wann musste ich die Aktien von Xvivo Perfusion kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Xvivo Perfusion from 12/12/2024 amounting to 0 SEK, you needed to have the stock in your portfolio before the ex-date on 12/12/2024.

When did Xvivo Perfusion pay the last dividend?

The last dividend was paid out on 12/12/2024.

What was the dividend of Xvivo Perfusion in the year 2023?

In the year 2023, Xvivo Perfusion distributed 0 SEK as dividends.

In which currency does Xvivo Perfusion pay out the dividend?

The dividends of Xvivo Perfusion are distributed in SEK.

All fundamentals about Xvivo Perfusion

Our stock analysis for Xvivo Perfusion Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Xvivo Perfusion Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.